Kim E, Ko HH, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 94
Paginas: 5-14
Archivo PDF: 84.78 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-99.

2. Pereira BJ. Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant 1995; 10(Suppl. 1): 58-67.

3. Fishman JA, Rubin RH, Koziel MJ, Periera BJ. Hepatitis C virus and organ transplantation. Transplantation 1996; 62: 147-54.

4. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.

5. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2007; 21(Suppl C): 5C-24C.

6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

8. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919-34.

9. Morales JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol 2002; 22: 365-74.

10. Hammoud H, Haem J, Laurent B, et al. Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 1996; 11(Suppl 4): 54-5.

11. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-70.

12. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805.

13. Huang CC, Liaw YF, Lai MK, Chu SH, Chuang CK, Huang JY. The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 1992; 53: 763-5.

14. Roth D. Hepatitis C virus: the nephrologist’s view. Am J Kidney Dis 1995; 25: 3-16.

15. Ponz E, Campistol JM, Barrera JM, et al. Hepatitis C virus antibodies in patients on hemodialysis and after kidney transplantation. Transplant Proc 1991; 23: 1371-2.

16. Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C—its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55: 273-6.

17. Berthoux F. Hepatitis C virus infection and disease in renal transplantation. Nephron 1995; 71: 386-94.

18. Chan TM, Lok AS, Cheng IK. Hepatitis C in renal transplant recipients. Transplantation 1991; 52: 810-3.

19. Klauser R, Franz M, Traindl O, et al. Hepatitis C antibody in renal transplant patients. Transplant Proc 1992; 24: 286-8.

20. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-33.

21. Roth D, Zucker K, Cirocco R, et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886-9.

22. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454-60.

23. Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494-9.

24. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704-12.

25. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343-53.

26. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 19(Suppl. 3): iii72-6.

27. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Jr., Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999; 67: 272-5.

28. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433-40.

29. Cosio FG, Sedmak DD, Henry ML, et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054-9.

30. Morales JM, Campistol JM, Andres A, Rodicio JL. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6: 511-5.

31. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608-14.

32. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-81.

33. Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83: 853-7.

34. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferonalpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999; 31: 2887-9.

35. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55: 220-6.

36. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil- Vernet S, Grinyo JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003;3:357-60.

37. Fabrizi F, Martin P, Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. Gastroenterol Clin North Am 2004; 33: 655-70, xi.

38. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.

39. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-9.

40. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha- 2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-8.

41. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-7.

42. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23.

43. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-9.

44. Casanovas. Interferon may be useful in hemodialysis patients with hepatitis C virus chronic infection who are candidates for kidney transplant. Transplant Proc 1995; 27: 2229.

45. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 1170-7.

46. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J Viral Hepat 2001; 8: 287-92.

47. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis Cassociated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-80.

48. Sporea I, Sirli R, Golea O, Totolici C, Danila M, Popescu A. Peg- Interferon Alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Rom J Gastroenterol 2004; 13: 99-102.

49. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-21.

50. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575-80.

51. Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha- interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104-6.

52. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-6.

53. Kakimoto K, Takahara S, Kokado Y, et al. [A case of allograft rejection induced by the interferon-alpha therapy to hepatitis type C after renal transplantation]. Hinyokika Kiyo 1994; 40: 529-32.

54. Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-8.

55. Fabrizi F, Martin P, et al. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opin Organ Transplant 2006; 11: 583.

56. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625-8.

57. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-70.

58. Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677-83.

59. Shu KH, Lan JL, Wu MJ, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77: 1894-6.

60. Tang S, Cheng IK, Leung VK, et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-8.

61. Zeman M, Campbell P, Bain VG. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol 2006; 20: 427-31.

62. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007; 41: 216-20.

63. Mukherjee S, Ariyarantha K. Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin. Transplantation 2007; 84: 1374-5.

64. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 1681-7.

65. Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998; 30: 611-3.

66. Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 1999; 31: 130-4.

67. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000; 15(Suppl 8): 74-6.

68. Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30: 110-4.

69. Calanca LN, Fehr T, Jochum W, et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol 2007; 39: 54-8.

70. Adinolfi LE, Andreana A, Utili R, Zampino R, Ragone E, Ruggiero G. HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Am J Gastroenterol 1998; 93: 2162-6.

71. Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8: 61-4.

72. Pham HP, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54: 1311-9.

73. Cattral MS, Hemming AW, Wanless IR, et al. Outcome of longterm ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999; 67: 1277-80.

74. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29: 783.

75. Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-92.

76. Fontaine H, Vallet-Pichard A, Equi-Andrade C, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853-7.

77. Karaca C, Besisik F, Akyuz F, Dincer D, Sever MS, Okten A. Ribavirin treatment in patients with chronic hepatitis C infection who had renal transplantation. Dig Surg 2005; 22: 113.

78. Fontaine. Histopathological efficacy of ribavirin monotherapy in hepatitis C virus positive renal transplant patients. Transplantation 2005; 79: 1771.

79. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 69: 991-4.

80. Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989-90.

81. Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of lowdose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 1988; 45:402-5.

82. Black M, Peters M. Alpha-interferon treatment of chronic hepatitis C: need for accurate diagnosis in selecting patients. Ann Intern Med 1992; 116: 86-8.

83. Durlik M, Gaciong Z, Rowinska D, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11(Suppl. 1): S135-9.

84. Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254-8.

85. Luciani G, Bossola M, Muscaritoli M, et al. Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. J Nephrol 2003; 16: 417-20.

86. Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol 2005; 3: S113-7.

87. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-61.

88. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000;70:255-61.

89. Chan TM, Wu PC, Lok AS, Lai CL, Cheng IK. Clinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantation. Nephron 1995; 71: 213-7.

90. Heydtmann M, Freshwater D, Dudley T, et al. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006; 6: 825-33.

91. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-93.

92. Konishi I, Horiike N, Michitaka K, et al. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy. Intern Med 2004; 43: 931-4.

93. Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 2004; 24(Suppl. 2): 33-8.

94. Carbognin SJ, Solomon NM, Yeo FE, et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transplant 2006; 6: 1746-51.